#ClinicSpeak: what does personalised medicine mean to you?

Personalised or precise, when it comes to medicine does it make a difference? #ClinicSpeak #MSBlog 

It's that time of year again; time for  the European Charcot Foundation meeting in Baveno. The programme is below. I am scheduled to speak on 'Personalized Medicine' on Friday. I have never done a talk on this topic so it is down to the drawing boards; I need a set of new slides and some inspiration. The following is Wikipedia's definition

'Personalized medicine is a medical procedure that separates patients into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease.'

I think it will be important to differentiate personalised medicine from precision medicine

'Precision medicine (PM) is a medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.'

It would help me if  you could give me some kind of steer or guidance from you. What does personalised medicine mean to you? Is the care you receive personalised? Am I missing the point is it about how your team engages with you, or is it about your treatment or management? Is the NHS's drive to care pathways and personalised care plans compatible with your understanding of personalised medicine? Should personalised medicine be delivered by a computer algorithms or humans? Is humanised medicine more important? Help! Thanks. 





Program

The theme of this year’s Annual Meeting: Multiple Sclerosis' Treatment in Practice promises interesting debates amongst researchers and clinical practitioners. 
The XXIV ECF Lecture will be given by Prof. Dr. Gilles Edan, Head of the Neuroscience Department Pontchaillou Hospital, Central University Hospital of Rennes, France.
The Scientific Committee of the 24th Annual Meeting: G. Comi (president), M. Clanet, G. Edan, F. Fazekas, H.P. Hartung, L. Kappos, H. Lassmann, J. Palace 

Thursday November 24, 2016

10:15 – 10:45
Welcome Coffee
 
10:45 – 11:45
Satellite Symposium EXCEMED - Excellence in Medical Education
 
11:45 – 12:45
Industry-sponsored Symposium

12:45 – 13:15
Light Lunch

13:15 - 14:15
XXIV ECF Lecture 

DMD Treatment Approval for MS: 20 Years Later!
14:15 - 16:00
Session I: TARGETS FOR INTERVENTIONS




B Cells Dependent Immune Mechanism as a Target for Intervention
Pathophysiology of MS Variants: Treatment Implications
H. Lassmann
Cytokines: Still a Relevant Target for MS Treatment?
R. Hohlfeld
The Blood-Brain Barrier in MS: a Target for Treatment?
E. de Vries
Q&A and Discussion
 
16:00 - 16:30
Coffee Break and Live Stream Poster Presentations 

16:30 - 18:00
Session II: LESSONS FROM CLINICAL TRIALS

Methodology Problems: Old and New Solutions
P. S. Soerensen
What do we Learn from Treatment Failures
How to Compare Efficacy Profiles of Treatments (Meta-Analysis)
M.P. Sormani
Q&A and Discussion
 
18:00 – 18:15
Coffee Break

18:15 – 19:15
Industry-sponsored Symposium
 
19:15 – 20:15
Welcome Cocktail 


Friday November 25, 2016

07:15 - 07:30
Light Breakfast and Coffee
 
07:30 - 08:30
Industry-sponsored Symposium
 
08:30 - 10:15
Session III: POST MARKETING STUDIES




Methodological Aspects and Evidences
M. Trojano
10 Year Prospective Observation UK Study
Safety and Tolerability
M. Clanet
Adherence in MS
T. Ziemssen
Q&A and Discussion
 
10:15 – 11:15
Coffee Break and Poster Viewing

11:15 - 13:00
Session IV: IMPROVING ASSESSMENTS
Chair: L. Patrucco




Cognition and Fatigue
IK. Penner
Wearable Devices for Remote Control
Patients Reported Outcomes
Q&A and Discussion

13:00 - 14:00
Lunch

14:00 - 15:45
Session V: TREATMENT INDIVIDUALIZATION




Personalized MedicineG. Giovannoni
MS Prognostic Aspects
Role of Omics
M. Comabella López
Role of the Organization
G. Comi
Q&A and Discussion
 
15:45 - 16:15
Coffee Break

16:15 - 18:00
Session VI: MONITOR AND TREATMENT




Assessment of Treatment Response
MRI Monitoring
C. Enzinger
Neurophysiology Methods
Safety Monitoring
H. Wiendl
Q&A and Discussion

18:00 – 18:15
Coffee Break

18:15 – 19:15
Industry-sponsored Symposium




Saturday November 26, 2016

08:30 - 10:15
Session VII: TREATMENT DECISIONS
Chair: D. Miller




Breaking Through Disease
Starting a Treatment
Stopping a Treatment
Sharing Decisions with Patients
Q&A and Discussion

10:15 - 10:45
Coffee Break

10:45 - 12:00
Session VIII: MS TREATMENT IN WOMEN AND CHILDREN




Effects of Treatment on Reproduction
Treatment Decisions before and during Pregnancy
MS Treatment during Puerperium and Lactation
Pediatric MS
Q&A and Discussion

12:00 - 12:30
Young Investigator Awards

12:30 - 13:00
Concluding Remarks
13:00 - 14:00
Lunch


Labels: , , ,